Company news

Novavax, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Novavax to Participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference

November 22, 2021

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines

November 16, 2021

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

November 14, 2021

Novavax Reports Third Quarter 2021 Financial Results and Operational Highlights

November 3, 2021

Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand

November 2, 2021

Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency

October 31, 2021

Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia

October 28, 2021

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

October 26, 2021

Novavax Announces Leadership Appointment and Updates

October 3, 2021

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

September 7, 2021

Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants

August 29, 2021

Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems

August 24, 2021

Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance

August 15, 2021

Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights

August 4, 2021

Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine

August 3, 2021

Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously

June 13, 2021

Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine

June 10, 2021

Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea

May 21, 2021

Novavax Reports First Quarter 2021 Financial Results and Operational Highlights

May 9, 2021

Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility

May 5, 2021

Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

May 2, 2021

Novavax Announces Leadership Updates

April 12, 2021

Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover

April 4, 2021

Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

February 28, 2021

Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan

February 25, 2021

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico

February 21, 2021

Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

February 17, 2021

Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea

February 14, 2021

Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization

February 3, 2021

Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine

February 2, 2021

Novavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada

February 1, 2021

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

January 27, 2021

Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine

January 21, 2021

Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer

January 14, 2021

Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine

January 6, 2021

Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico

December 27, 2020

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine

December 15, 2020

Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors

December 8, 2020

Novavax Announces COVID-19 Vaccine Clinical Development Progress

November 29, 2020

Novavax Reports Third Quarter 2020 Financial and Operational Results

November 8, 2020

Novavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine

November 3, 2020

Novavax Appoints Biopharmaceutical Industry Veteran Gregg Alton to Board of Directors

November 2, 2020

Novavax Announces Facility Expansion to Support Global Vaccine Development

November 1, 2020

Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update

October 26, 2020

Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure

October 12, 2020

Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom

September 23, 2020

Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually

September 14, 2020

Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine

September 1, 2020

Novavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine

August 30, 2020

Novavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of COVID-19 Vaccine

August 23, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 69 decks. Every deck is listed under its year.